Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

DUSA Pharmaceuticals, Inc. Schedules Conference Call and Second Quarter 2003 Results.


Business Editors

WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 7, 2003

DUSA DUSA Deputy Under Secretary of the Army
DUSA Deakin University Student Association
DUSA Dundee University Students' Association (Scotland)
DUSA Designated Unclassified Subject Area
 Pharmaceuticals, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
 NMS See NetWare Management System. : DUSA) announces that its Q2 2003 corporate highlights and financial results press release will be issued on Tuesday, August 12th at 7:30 a.m., to be followed by a conference call at 8:45 a.m.


Tuesday, August 12th, 2003 - 8:45 a.m. Eastern
If calling from the US or Canada use the following toll-free number:
800.936.4602
Password -  DUSA

For International callers use
507.726.3331
Password - DUSA

You will also be able to listen to a replay of the conference call
until August 18th using the following numbers:
North American callers 800.334.2128
International callers 580.431.2723



The call will be accessible on our web site after Wednesday, August 13th at www.dusapharma.com.

DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in the development of Levulan(R) Photodynamic Therapy photodynamic therapy
n.
A type of phototherapy in which a nontoxic light-sensitive compound that has been injected into a patient is exposed selectively to light, whereupon it becomes toxic to targeted malignant and other diseased cells.
 (PDT PDT
abbr.
Pacific Daylight Time


PDT Pacific Daylight Time

PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del PacĂ­fico

PDT 
) and Photodetection (PD) for multiple medical indications. PDT and PD utilize light-activated compounds such as Levulan(R) to induce a therapeutic or detection effect. DUSA is a world leader in topically or locally applied PDT and PD. The Company maintains offices in Wilmington, MA, Valhalla, NY, and Toronto, Ontario.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Aug 7, 2003
Words:202
Previous Article:Great Lakes REIT Reports $0.11 EPS and $0.44 FFO Per Common Share for Second Quarter 2003.
Next Article:American Spectrum Realty Reports Second Quarter Results; Refocusing Strategy on Target.
Topics:



Related Articles
KILL BW0426, DUSA-PHARMACEUTICALS and KILL BW0433, CQN-DUSA-PHARMACEUTICALS.
DUSA Pharmaceuticals, Inc. Announces Conference Call to Report On Second Quarter Financial Results.
DUSA Pharmaceuticals, Inc. Schedules Conference Call And First Quarter 2003 Results.
DUSA Pharmaceuticals, Inc. Schedules Conference Call And Third Quarter 2003 Results.
DUSA Announces First Quarter Levulan Kerastick End-User Sales; Positive Response at Laser Meeting.
DUSA Announces Increased Second Quarter Levulan'R' Kerastick'R' and BLU-U'R' End-User Sales.
DUSA Pharmaceuticals, Inc. to Host First Quarter 2005 Corporate Highlights and Financial Results Conference Call.
DUSA Pharmaceuticals, Inc. to Host Conference Call Re Second Quarter 2005 Levulan'R' Kerastick'R' and BLU-U'R' Sales Update.
DUSA Pharmaceuticals, Inc. To Host Second Quarter 2005 Corporate Highlights And Financial Results Conference Call.
DUSA Pharmaceuticals, Inc. to Host Third Quarter 2005 Corporate Highlights and Financial Results Conference Call.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles